Modelling outbreak response strategies for preventing spread of emergent Neisseria gonorrhoeae strains in men who have sex with men in Australia

The ability to treat gonorrhoea with current first-line drugs is threatened by the global spread of extensively drug resistant (XDR) Neisseria gonorrhoeae (NG) strains. In Australia, urban transmission is high among men who have sex with men (MSM) and emergence of an imported XDR NG strain in this population could result in an epidemic that would be difficult and costly to control. An individual-based, anatomical site-specific mathematical model of NG transmission among Australian MSM was developed and used to evaluate the potential for elimination of an emergent XDR NG strain under a range of case-based and population-based test-and-treat strategies. When applied upon detection of the imported strain, these strategies enhanced the probability of elimination and reduced the outbreak size compared with current practice. The most effective strategies combined testing targeted at regular and casual partners with increased rates of population testing. However, even with the most effective strategies, outbreaks could persist for up to 2 years post-detection. Our simulations suggest that local elimination of emergent NG XDR strains can be achieved with high probability using combined case-based and population-based test-and-treat strategies. These strategies may be an effective means of preserving current treatments in the event of wider XDR NG emergence.

[1]  M. Unemo,et al.  Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial. , 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  J. Hocking,et al.  Models of gonorrhoea transmission from the mouth and saliva. , 2019, The Lancet. Infectious diseases.

[3]  Monica Lahra,et al.  Emergence and spread of ciprofloxacin-resistant Neisseria gonorrhoeae in New South Wales, Australia: lessons from history. , 2019, The Journal of antimicrobial chemotherapy.

[4]  D. Lewis New treatment options for Neisseria gonorrhoeae in the era of emerging antimicrobial resistance. , 2019, Sexual health.

[5]  T. Street,et al.  P675 Two recent cases of extensively drug-resistant (XDR) gonorrhoea in the united kingdom linked to a european party destination , 2019, Poster Presentations.

[6]  J. Hocking,et al.  Kissing may be an important and neglected risk factor for oropharyngeal gonorrhoea: a cross-sectional study in men who have sex with men , 2019, Sexually Transmitted Infections.

[7]  T. Street,et al.  Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018 , 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[8]  D. Eyre,et al.  Genetic relatedness of ceftriaxone-resistant and high-level azithromycin resistant Neisseria gonorrhoeae cases, United Kingdom and Australia, February to April 2018 , 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[9]  R. Guy,et al.  Gonorrhoea gone wild: rising incidence of gonorrhoea and associated risk factors among gay and bisexual men attending Australian sexual health clinics. , 2019, Sexual health.

[10]  Monica Lahra,et al.  Treatment for pharyngeal gonorrhoea under threat. , 2018, The Lancet. Infectious diseases.

[11]  M. Unemo,et al.  Multidrug-resistant Neisseria gonorrhoeae failing treatment with ceftriaxone and doxycycline in France, November 2017. , 2018, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[12]  W. Demczuk,et al.  Cooperative Recognition of Internationally Disseminated Ceftriaxone-Resistant Neisseria gonorrhoeae Strain , 2018, Emerging infectious diseases.

[13]  M. Gambhir,et al.  Neisseria gonorrhoeae Transmission Among Men Who Have Sex With Men: An Anatomical Site-Specific Mathematical Model Evaluating the Potential Preventive Impact of Mouthwash , 2017, Sexually transmitted diseases.

[14]  D. Lewis,et al.  Mixed gonococcal infections in a high-risk population, Sydney, Australia 2015: implications for antimicrobial resistance surveillance? , 2017, The Journal of antimicrobial chemotherapy.

[15]  Monica Lahra,et al.  Treatment guidelines after an outbreak of azithromycin-resistant Neisseria gonorrhoeae in South Australia. , 2017, The Lancet. Infectious diseases.

[16]  C. Bradshaw,et al.  Duration of gonorrhoea and chlamydia infection at the pharynx and rectum among men who have sex with men: a systematic review. , 2016, Sexual health.

[17]  J. Hocking,et al.  Early presentation of symptomatic individuals is critical in controlling sexually transmissible infections. , 2015, Sexual health.

[18]  J. Hocking,et al.  Oral and anal sex are key to sustaining gonorrhoea at endemic levels in MSM populations: a mathematical model , 2015, Sexually Transmitted Infections.

[19]  M. Unemo,et al.  Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future , 2014, Clinical Microbiology Reviews.

[20]  M. Russell,et al.  New Concepts in Immunity to Neisseria Gonorrhoeae: Innate Responses and Suppression of Adaptive Immunity Favor the Pathogen, Not the Host , 2011, Front. Microbio..

[21]  S. Tabrizi,et al.  Is it time to move to nucleic acid amplification tests screening for pharyngeal and rectal gonorrhoea in men who have sex with men to improve gonorrhoea control? , 2011, Sexual health.

[22]  C. Bourne,et al.  Is screening asymptomatic men who have sex with men for urethral gonorrhoea worthwhile? , 2010, Sexual health.

[23]  J. Tapsall,et al.  Analysis of trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Australia, 1997 2006. , 2007, The Journal of antimicrobial chemotherapy.

[24]  S. Garland,et al.  Re-infection of Neisseria gonorrhoeae and Chlamydia trachomatis infections among men who have sex with men , 2006, International journal of STD & AIDS.

[25]  M. Salter,et al.  The Health in Men and Positive Health cohorts A comparison of trends in the health and sexual behaviour of HIV-negative and HIV-positive gay men, 2002-2005 , 2006 .

[26]  P. Moodley,et al.  Ciprofloxacin-resistant gonorrhoea in South Africa , 2005, The Lancet.

[27]  J. Zenilman,et al.  Gonorrhoea reinfection in heterosexual STD clinic attendees: longitudinal analysis of risks for first reinfection , 2003, Sexually transmitted infections.

[28]  M. Mayo,et al.  Limited Local and Systemic Antibody Responses toNeisseria gonorrhoeae during Uncomplicated Genital Infections , 1999, Infection and Immunity.

[29]  K. Holmes,et al.  A trial of minocycline given after exposure to prevent gonorrhea. , 1979, The New England journal of medicine.